To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Validation of a clinical-… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA.

Journal article
Authors Caty Carrera
Natalia Cullell
Nuria Torres-Águila
Elena Muiño
Alejandro Bustamante
Antonio Dávalos
Elena López-Cancio
Marc Ribó
Carlos A Molina
Eva Giralt-Steinhauer
Carolina Soriano-Tárraga
Marina Mola-Caminal
Jordi Jiménez-Conde
Jaume Roquer
Cristófol Vives-Bauza
Rosa Díaz Navarro
Victor Obach
Juan Francisco Arenillas
Tomás Segura
Gemma Serrano-Heras
Joan Martí-Fàbregas
Marimar Freijo
Juan Antonio Cabezas
Turgut Tatlisumak
Laura Heitsch
Laura Ibañez
Carlos Cruchaga
Jin-Moo Lee
Daniel Strbian
Joan Montaner
Israel Fernández-Cadenas
Published in Neurology
Volume 93
Issue 9
Pages e851-e863
ISSN 1526-632X
Publication year 2019
Published at Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Pages e851-e863
Language en
Subject categories Neurology


To validate the Genot-PA score, a clinical-genetic logistic regression score that stratifies the thrombolytic therapy safety, in a new cohort of patients with stroke.We enrolled 1,482 recombinant tissue plasminogen activator (rtPA)-treated patients with stroke in Spain and Finland from 2003 to 2016. Cohorts were analyzed on the basis of ethnicity and therapy: Spanish patients treated with IV rtPA within 4.5 hours of onset (cohort A and B) or rtPA in combination with mechanical thrombectomy within 6 hours of onset (cohort C) and Finnish participants treated with IV rtPA within 4.5 hours of onset (cohort D). The Genot-PA score was calculated, and hemorrhagic transformation (HT) and parenchymal hematoma (PH) risks were determined for each score stratum.Genot-PA score was tested in 1,324 (cohort A, n = 726; B, n = 334; C, n = 54; and D, n = 210) patients who had enough information to complete the score. Of these, 213 (16.1%) participants developed HT and 85 (6.4%) developed PH. In cohorts A, B, and D, HT occurrence was predicted by the score (p = 2.02 × 10-6, p = 0.023, p = 0.033); PH prediction was associated in cohorts A through C (p = 0.012, p = 0.034, p = 5.32 × 10-4). Increased frequency of PH events from the lowest to the highest risk group was found (cohort A 4%-15.7%, cohort B 1.5%-18.2%, cohort C 0%-100%). The best odds ratio for PH prediction in the highest-risk group was obtained in cohort A (odds ratio 5.16, 95% confidence interval 1.46-18.08, p = 0.009).The Genot-PA score predicts HT in patients with stroke treated with IV rtPA. Moreover, in an exploratory study, the score was associated with PH risk in mechanical thrombectomy-treated patients.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-02-24